This educational activity is based on case presentations and subsequent small group discussions of patients with hematologic malignancies that are being evaluated, treated and followed in the Department of Hematology and Oncology, and that have diagnostic or follow-up material evaluated in the Division of Hematopathology. The goal of this multimodality approach is to ensure that the best patient care is being delivered by both Hematologists/Oncologists and Pathologists.
Key Words:
- CME
- MCW
- Pathology
- Clinical Pathology
- Molecular Pathology
- Hematologic Neoplasms
- Hematologic Tests
- Hematologic Diseases
- Morphological and Microscopic Findings
- Diagnostic Techniques and Procedures
- Clinical Laboratory Techniques
- Hemic and Immune Systems
- Differential Diagnosis
- Pathological Processes
- Neoplastic Cell Transformation
- Hematologists
- Oncologists
- Hematopathologists
Participants who engage in this educational intervention will be able to:
Hematologists/Oncologists:
- Identify appropriate ordering of expensive, ancillary diagnostic testing
- Describe the salient morphologic, immunophenotypic, cytogenetic and molecular features of common hematologic malignancies
Hematopathologists:
- Discuss emergent therapeutic options and availability of clinical trials, and how they apply to patients diagnosed in our service
- Utilize and constantly update themselves with the clinical practices of the Department of Hematology and Oncology, in order to continue to improve outcomes and provide optimal patient care
Activity Director
Professor of Pathology
Director of Hematopathology
Department of Pathology
Faculty Pillar Director, Robert D. and Patricia E. Kern Institute for the Transformation of Medical Education
Medical College of Wisconsin
Professor of Pathology
Director of Hematopathology
Department of Pathology
Faculty Pillar Director, Robert D. and Patricia E. Kern Institute for the Transformation of Medical Education
The following persons in control of content disclosed the following financial relationships which were reviewed via the MCW conflict of interest resolution process and resolved.
Name | Company | Role |
---|---|---|
Ehab Atallah, MD | Novartis | Consultant; Presenter; Advisory Committee |
Ehab Atallah, MD | Takeda | Research; Consulting |
Ehab Atallah, MD | Abbvie | Research/Consulting |
Ehab Atallah, MD | Jazz | Presenter |
Ehab Atallah, MD | Pfizer | Consultant |
Ehab Atallah, MD | Amgen | Consultant |
Ehab Atallah, MD | BMS | Presenter |
Contact
- 1.00 AMA PRA Category 1 Credit(s)™AMA PRA Category 1 Credit(s)™
- 1.00 Hours of ParticipationHours of Participation credit.